Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

RTI Biologics Inc Raises Low End Of Prior FY 2013 Revenue Guidance To A Range Above Analysts' Estimates; Reaffirms FY 2013 EPS Guidance; Issues Q2 2013 Guidance In Line With Analysts' Estimates


Thursday, 25 Apr 2013 08:09am EDT 

RTI Biologics Inc announced that for fiscal 2013, it expects revenues to be between $179-$182 million, net income per fully diluted share to be in the range of $0.17 to $0.19. For the second quarter of 2013, the Company expects revenues to be between $42 million and $43 million, and net income per fully diluted share to be approximately $0.03. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $178 million and EPS of $0.17 for fiscal 2013; revenue of $43 million and EPS of $0.03 for the second quarter of 2013. 

Company Quote

4.94
 --
25 Nov 2014